Curcumin analogue C66 ameliorates mouse cardiac dysfunction and structural disorders after acute myocardial...

Area of Science:

• Cardiovascular Science
• Pharmacology
• Molecular Biology

Background:

• Myocardial infarction (MI) is a major cause of cardiovascular disease, characterized by inflammation and tissue damage.
• Curcumin analogues, like C66, have shown anti-inflammatory properties in previous studies.
• The potential of C66 to mitigate cardiac dysfunction post-MI requires investigation.

Purpose of the Study:

• To evaluate the efficacy of C66 in improving cardiac function after MI.
• To assess the impact of C66 on cardiac structural remodeling, inflammation, and apoptosis.
• To elucidate the underlying molecular mechanisms of C66's cardioprotective effects.

Main Methods:

• Administration of C66 (5 mg/kg) to a rat model of myocardial infarction for 4 weeks.
• Assessment of cardiac function, infarct size, cardiac hypertrophy, and fibrosis.
• In vitro studies using H9C2 cardiomyocytes under hypoxic conditions to evaluate anti-inflammatory and anti-apoptotic effects.
• Investigation of the role of JNK phosphorylation in mediating C66's effects.

Main Results:

• C66 treatment significantly improved cardiac function and reduced infarct size post-MI.
• C66 effectively attenuated cardiac pathological hypertrophy and fibrosis in non-infarct regions.
• In vitro, C66 demonstrated anti-inflammatory and anti-apoptotic effects on cardiomyocytes under hypoxia.
• C66 inhibited JNK phosphorylation, and JNK activation reversal abolished C66's cardioprotective benefits.

Conclusions:

• Curcumin analogue C66 exhibits significant cardioprotective effects against myocardial infarction.
• C66 alleviates cardiac dysfunction and pathological tissue injury by inhibiting JNK signaling.
• C66 represents a promising therapeutic agent for managing myocardial infarction and related cardiovascular complications.